Mutations in the bZip region of the CEBPA gene: A novel prognostic factor in patients with acute myeloid leukemia

Abstract

AbstractBackgroundHematopoiesis, the process of blood cell formation involves on a complex network of transcription factors. Among them, the CCAAT‐enhancer‐binding protein alpha (CEBPA) plays a crucial role in maintaining the balance between myeloid proliferation and differentiation. Imbalances in this network can lead to disrupted differentiation and contribute to the development of malignant diseases.AimUnderstanding of disease development and explore potential therapeutic strategies for hematological disorders associated CEPBA gen.Materials and MethodsThe research involved a comprehensive analysis of CEBPA gene mutations in the context of acute myeloid leukemia (AML). This encompassed a thorough exploration of point mutations and double mutations in AML patients.ResultsIn the context of acute myeloid leukemia (AML), mutations in the CEBPA gene, especially point mutations, are frequently observed. A significant number of AML patients present with double mutations in CEBPA, which have been linked to a more favorable prognosis in terms of overall survival and event‐free survival. These patients also tend to exhibit enhanced responsiveness to treatment. Discussion: Unraveling the intricate interplay of transcription factors, particularly CEBPA, holds significant implications for decoding the mechanisms governing hematopoiesis. This understanding offers a potential avenue for deciphering disease development and devising novel therapeutic strategies for hematological disorders.ConclusionThe findings underscore that CEBPA mutations correlate with enhanced overall survival and event‐free survival, with relevance to those presenting within the bZip framework. This knowledge may contribute to advancing personalized treatments for hematological conditions.